prediction

If regulators accept the sleep-apnea data, Lilly gains a second disease-specific use for an oral obesity drug and a cleaner pitch to patients who do not want injections.

A prediction by MY READ. Statements are as reported by the cited publishers — not verified by DecisionGateway.

If regulators accept the sleep-apnea data, Lilly gains a second disease-specific use for an oral obesity drug and a cleaner pitch to patients who do not want injections.
pattystraphousePublished 2026-11-09 Read source

Discussion

0/2000

Related claims